About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
  • Cereblon E3 Ligase Modulation (CELMoD® Agents) in Targeted Protein Degradation

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


    Therapeutic Potential of CELMoD Agents

    CELMoD agents are hypothesized to promote the degradation of target proteins that are important for the biology of multiple diseases; this therapeutic approach has been demonstrated in preclinical studies.1 Proteins targeted by CELMoD agents play an important role in cell apoptosis, differentiation, and proliferation and are deregulated in hematologic malignancies including multiple myeloma, leukemia, diffuse large B-cell lymphoma, and myelodysplastic syndromes.2-6

    A large proportion of these target proteins are transcription factors and are difficult to inhibit, at least in part because of their intracellular localization.1,7,8 Degradation of transcription factors by CELMoD agents is a strategy to address proteins important in disease pathophysiology.5 CELMoD agents modulate the function of the ubiquitin proteasome system, or UPS, by co-opting cereblon (CRBN), a component of a ubiquitin E3 ligase complex that is required for the function of protein degradation machinery.1

    CELMoD Agents and the CRBN/E3 Ligase Pathway

    CRBN is the target protein receptor on the CRL4CRBN E3 ligase complex in the UPS.2,9,10 Preclinical studies demonstrated that CRBN was necessary for the immunomodulatory and anti-myeloma effects of the IMiD® agents lenalidomide and pomalidomide.1 These agents, analogs of thalidomide, represent a subtype of agents now known as the CELMoD agents.1 The interaction of IMiD agents with CRBN has been shown to enhance the binding and ubiquitination of the transcription factors Ikaros and Aiolos; proteasome-dependent destruction of Ikaros and Aiolos in preclinical studies was shown to directly reduce proliferation of myeloma cells and activate T cells.1 CRBN is expressed in a variety of tissues, with the highest levels in immune cells detected in T and B cells.11,12

    This understanding of the IMiD agents’ mechanism of action provided rationale for the identification of potential novel modulators of CRBN. 1 Like the IMiD agents lenalidomide and pomalidomide, several novel, more potent CRBN modulators have been shown to target Ikaros and Aiolos in preclinical studies.13-15 CELMoD agents that target proteins other than Ikaros and Aiolos via CRBN modulation are also in development.2,16 In preclinical studies, co-opting of CRBN mediated the ubiquitination and proteasomal degradation of substrate proteins and has been shown to underlie the anti-proliferative and immunomodulatory activities of CELMoD agents, including the IMiD agents lenalidomide and pomalidomide, in malignancies including multiple myeloma, lymphoma, and del(5q) myelodysplastic syndromes.2,6,10,17-20 The redirection of CRBN by lenalidomide has been shown to have tumoricidal effects in non-Hodgkin lymphoma and multiple myeloma through inhibition of expression of oncogenes, such as IRF4.6,21-23 In del(5q) myelodysplastic syndromes, modulation of the CRL4CRBN complex by lenalidomide has been shown to induce ubiquitination of casein kinase 1A1 (CK1α), resulting in its degradation.21 In multiple myeloma, pomalidomide exhibits tumoricidal, immunomodulatory, and anti-stromal support activities through modulation of the CRL4CRBN complex.1 Preclinical studies of two CELMoD agents have demonstrated increased affinity for CRBN and higher potency for CRBN-modulating activity due to rapid and efficient substrate degradation in multiple myeloma and immune effector cells; these features were associated with enhanced antitumor effects and immune stimulation, even in cells that were resistant to IMiD agents.13-15

    Activity of IMiD Agents in Multiple Myeloma

    The immunomodulatory properties of the IMiD agents lenalidomide and pomalidomide have been demonstrated in preclinical studies.2,24-26 IMiD agents have been found to increase activation and proliferation of T cells, production of IL-2, and activity of CD8+ effector T cells.2,24,25 Stimulation and expression of natural killer (NK) cells, NK cell–mediated lysis via antibody-dependent cell-mediated cytotoxicity, and direct NK cell–mediated killing were also enhanced by IMiD agents.24,26 Based in part on these data, we are investigating the role of lenalidomide and pomalidomide in combination with various agents in multiple myeloma.

    In addition to immunomodulatory properties, IMiD agents are also hypothesized to exert tumoricidal and antiangiogenic activity.23

    Preclinical studies demonstrated increased anti-myeloma activity of IMiD agents in combination with dexamethasone and certain proteasome inhibitors and monoclonal antibodies.27-33

    Activity of Novel CELMoD Agents in Multiple Myeloma

    CELMoD agents can confer differentiated activity against target proteins. Two CELMoD agents, iberdomide and CC-92480, have demonstrated higher affinity for CRBN and higher potency for CRBN modulation than IMiD agents in multiple myeloma cells.13-15 Compared to pomalidomide and lenalidomide, iberdomide bound to CRBN with higher affinity and demonstrated more rapid degradation of Ikaros and Aiolos in multiple myeloma cells.13 Furthermore, iberdomide inhibited multiple myeloma cell proliferation and resulted in  immunomodulatory effects in pomalidomide-resistant cells.13 Further preclinical studies demonstrated potent tumoricidal anti-multiple myeloma and immunostimulatory activity of iberdomide.14 CC-92480 is a novel CELMoD agent that has demonstrated single-agent antiproliferative effects in multiple myeloma cells and immunomodulation in preclinical studies.15 CC-92480 binds to CRBN with higher affinity and results in more efficient depletion of Ikaros and Aiolos than lenalidomide or pomalidomide.15 In a panel of 20 multiple myeloma cell lines, including several that were either resistant or refractory to IMiD agents, CC-92480 inhibited proliferation, induced apoptosis, and stimulated T cell activity and cytokine release more potently than lenalidomide or pomalidomide.15 These preclinical results have served as rationale for clinical development of the novel CELMoD agents iberdomide and CC-92480 in multiple myeloma.

    View Related Molecules


    1. Chaberlain PP, Cathers BE. Drug Discov Today Technol. 2019;31:29-34. PMID: 31200856
    2. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID: 24328678
    3. Fecteau JF, et al. Blood. 2014;124:1637-1644. PMID: 24990888
    4. Turturro F. Biomed Res Int. 2015;2015:484537. PMID: 25984532
    5. Ito T, Handa H. Int J Hematol. 2016;104:293-299. PMID: 27460676
    6. Zhang LH, et al. Br J Haematol. 2013;160:487-502. PMID: 23252516
    7. Verdine GL, Walensky LD. Clin Cancer Res. 2007;13:7264-7270. PMID: 18094406
    8. Lambert M, et al. Molecules. 2018;23.pii: E1479. PMID: 29921764
    9. Ito T, et al. Science. 2010;327:1345-1350. PMID: 20223979
    10. Lopez-Girona A, et al. Leukemia. 2012;26:2326-2335. PMID: 22552008
    11. The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000113851-CRBN/tissue (accessed 11 December 2019).
    12. Immunological Genome Project. http://www.immgen.org/databrowser/index.html. Search term: CRBN (accessed 11 December 2019).
    13. Bjorklund CC, et al. Leukemia. 2019;doi: 10.1038/s41375-019-0620-8. [Epub ahead of print]. PMID: 31719682
    14. Lonial S, et al. Blood. 2019;134(Suppl_1):3119.
    15. Lopez-Girona A, et al. Poster presented at ASH 2019 [abstract 1812].
    16. Nakayama Y, et al. J Immunol. 2017;199:2388-2407. PMID: 28848067
    17. Xu Y, et al. Blood. 2009;114:338-345. PMID: 19417207
    18. Krönke J, et al. Science. 2014;343:301-305. PMID: 24292625
    19. Lu G, et al. Science. 2014;343:305-309. PMID: 24292623
    20. Zhang LH, et al. Br J Haematol. 2013;160:487-502. PMID: 23252516
    21. Hollenbach P, et al. Blood. 2014;124 [abstract 3606].
    22. Yang T, et al. Cancer Cell. 2012;21:727-737. PMID: 22698399
    23. Shaffer AL, et al. Clin Cancer Res. 2009;15:2954-2961. PMID: 19383829
    24. Sehgal K, et al. Blood. 2015;125:4042-4051. PMID: 25869284
    25. Galustian C, et al. Expert Opin Biol Ther. 2004;4:1963-1970. PMID: 15571458
    26. Lapalombella R, et al. Blood. 2008;112:5180-5189. PMID: 18772452
    27. Rychak E, et al. Br J Haematol. 2016;172:889-901. PMID: 26914976
    28. Gandhi AK, et al. Curr Cancer Drug Targets. 2010;10:155-167. PMID: 20088798
    29. Chauhan D, et al. Blood. 2010;116:4906-4915. PMID: 20805366
    30. Das DS, et al. Br J Haematol. 2015;171:798-812. PMID: 26456076
    31. van der Veer MS, et al. Haematologica. 2011;96:284-290. PMID: 21109694
    32. Nijhof IS, et al. Clin Cancer Res. 2015;21:2802-2810. PMID: 25398450
    33. Boxhammer R, et al. Poster presented at ASCO 2015 [abstract 8588].